Intended for healthcare professionals


Manufacturer should also give incidence of “severe” adverse events

BMJ 1996; 313 doi: (Published 14 December 1996) Cite this as: BMJ 1996;313:1553
  1. Lorraine Traer-Clark
  1. Liaison organiser Lariam Action, 122 Balgores Lane, Gidea Park, Romford RM2 5JX

    EDITOR,—Lariam Action believes that the incidence of adverse reactions to prophylaxis with mefloquine is far greater than the 22% claimed by the manufacturer, and so we were interested to see that P J Barrett and colleagues' paper supports that view.1 The difference between the paper's finding that 41.4% of people who take the drug will experience an adverse event and the manufacturer's figure of 22% …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription